Cyclacel制药 CYCC 深 沪
已收盘 09-11 16:00:00 美东时间
6.365
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 6.365
- 总市值 1425.12万
- 52周最高 597.60
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 3.0801
- 委 比 0.00%
- 总股本 223.90万
- 历史最高 7067520.00
- 量 比 0
- 振 幅 0.00%
- 历史最低 40.944
- 每 手 1
- 风险率 3.56%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多BIO GREEN MED SOLUTION, INC. ANNOUNCES BUSINESS COMBINATION AGREEMENT TO ACQUIRE FUTURE NRG SDN. BHD.
<p>Bio Green Med Solution, Inc. (BGMS) has entered into a Business Combination Agreement (BCA) with Future NRG Sdn. Bhd. (Future NRG) for an all-stock share exchange transaction. The merger aims to create a next-generation environmental platform by combining essential safety and environmental services, focusing on regulatory-driven industries. The combined company will integrate niche sectors of fire safety and green waste treatment, providing a ...
06-04 20:10
Cyclacel Pharmaceuticals Q1 EPS $(0.04) Up From $(11.52) YoY, Sales $778.000K
Cyclacel Pharmaceuticals (NASDAQ:BGMS) reported quarterly losses of $(0.04) per share. This is a 99.65 percent increase over losses of $(11.52) per share from the same period last year. The company reported $778.000
05-15 04:32
Aterian, Inc. Announces Definitive Agreement for the Sale of its Marquee Brand Portfolio for $18 Million Subject to Adjustments
Aterian, Inc. announced the sale of its e-commerce brand portfolio, including Mueller Living, PurSteam, and others, to Trademark Global for $18 million, subject to adjustments. The deal requires shareholder approval and is expected to close in Q2 2026, with proceeds distributed to shareholders in Q3. Aterian also secured a $7 million strategic investment from David Lazar, who will become CEO following the transaction. Lazar has waived rights to a...
04-28 12:00
Bio Green Med Solution’s Strategic Shift and Q3 Results
Cyclacel Pharmaceuticals ( ($BGMS) ) has released its Q3 earnings. Here is a br...
2025-11-14 12:46
Cyclacel Pharmaceuticals: Recent Acquisition Completed
An update from Cyclacel Pharmaceuticals ( ($CYCC) ) is now available. On Septem...
2025-09-12 18:28
Cyclacel Pharmaceuticals Approves Key Shareholder Proposals
Cyclacel Pharmaceuticals ( ($CYCC) ) has provided an update. On September 4, 20...
2025-09-06 00:18
Cyclacel Pharmaceuticals Enters Warrant Exchange Agreement
Cyclacel Pharmaceuticals ( ($CYCC) ) has provided an update. On September 4, 20...
2025-09-05 04:40
Cyclacel Pharmaceuticals Exchanges Series C Warrants For 559,395 Common Shares In Agreement With Accredited Investors
On September 4, 2025, Cyclacel Pharmaceuticals, Inc. (the "Company") entered into a Warrant Exchange Agreement (the "Exchange Agreement") with certain accredited investors (the "Holders") of existing Series C common
2025-09-05 04:03
Cyclacel Pharmaceuticals Inc. Files Initial Statement of Beneficial Ownership for Ong Yee Lung
Cyclacel Pharmaceuticals Inc. has filed an initial statement of beneficial ownership, identifying Ong Yee Lung as the beneficial owner. The full filing can be accessed through the link below. Disclaim...
2025-09-02 18:14
Cyclacel Pharmaceuticals Inc. Files Initial Beneficial Ownership Statement for Kua Khai Loon
Cyclacel Pharmaceuticals Inc. has filed an initial statement of beneficial ownership, naming Kua Khai Loon as the beneficial owner. The full filing can be accessed through the link below. Disclaimer: ...
2025-09-02 18:14
